Retatrutide: Why the “Triple G” Agonist is the Future of Weight Loss
Retatrutide is a first-in-class GLP-1, GIP, and Glucagon triple agonist that delivers up to 28.7% weight loss in Phase 3 trials — while preserving lean muscle mass far better than semaglutide or tirzepatide.
